FREE Shipping on all US Orders
Ingredient spotlight: bhringaraj — the 62.5% shedding reduction in 24 weeks, the 5-AR inhibition mechanism, and what makes it the best-evidenced Ayurvedic hair botanical.
A 2025 clinical trial (54 participants, 24 weeks) found standardised oral Eclipta alba extract reduced comb test hair shedding by 62.5% (p<0.0001). A 2023 lab study found Eclipta alba extract comparable to 5-AR inhibitors including finasteride in vitro. The primary bioactive — wedelolactone — has documented 5-AR inhibition, anti-inflammatory, and anagen-promoting properties. The best-evidenced Ayurvedic hair botanical in the series. Here is the complete picture.
The 62.5% shedding reduction in the 2025 JAIMS trial is the most dramatic clinical result of any Ayurvedic botanical this series has covered — and it is the result of the most recent and best-designed trial. The honest caveat is the study design: open-label, pre-post, no placebo control. The result needs a randomised placebo-controlled trial to be fully confirmed. But the result is large enough, statistically significant enough, and mechanistically supported enough to position bhringaraj as the most clinically credible Ayurvedic hair botanical available.
In brief: Bhringaraj (Eclipta alba, also called Eclipta prostrata) is the most clinically evidenced Ayurvedic botanical for hair loss in this series. A 2025 prospective clinical trial published in the Journal of Ayurveda and Integrated Medical Sciences (Mote et al., January 2026) — 54 participants, 24 weeks — found standardised oral Eclipta alba extract reduced 60-second comb test hair counts by 62.5% (p<0.0001). A 2023 laboratory study found Eclipta alba extract comparable to 5-alpha reductase inhibitors including finasteride in vitro. Wedelolactone — the primary bioactive coumestan compound — has documented 5-AR inhibition, anti-inflammatory, and anagen-promoting properties. The honest caveats are equally important: the 2025 trial was open-label without a placebo control, and the 5-AR comparison was in vitro not in vivo. Here is the complete picture.
What is bhringaraj and what are its bioactive compounds?
Bhringaraj is a small annual herb of the Asteraceae (sunflower) family — characterised by small white daisy-like flowers and dark green lanceolate leaves, growing naturally in tropical and subtropical regions across India, Southeast Asia, Brazil, and other moist environments. (cite index="26-1">Every part of the plant contains medicinally active compounds, though the leaves are most commonly used in hair formulations.
The primary bioactive compounds relevant to hair:
Wedelolactone is the compound most responsible for bhringaraj's pharmacological activity relevant to hair. It is a coumestan — a type of phytoestrogen and potent biological active — with documented 5-alpha reductase inhibitory activity. The 2023 Chakraborty et al. study (International Journal of Pharmaceutical Quality Assurance) confirmed Eclipta alba extract's 5-AR inhibitory activity in vitro, comparable to finasteride in the laboratory setting. Wedelolactone also has documented anti-inflammatory activity through NF-κB pathway inhibition — addressing the scalp inflammatory environment that the PIILIF pathway series covered extensively.
(cite index="28-1">The herb is rich in bioactive constituents including wedelolactone, ecliptine, luteolin, and flavonoids, which exhibit potent antioxidant, anti-inflammatory, and vasodilatory properties that enhance the microcirculation of the scalp and promote healthy hair growth. Luteolin is a flavone with documented 5-lipoxygenase inhibitory activity — addressing the same inflammatory pathway that frankincense's boswellic acids target in the facial care range. Ecliptine is an alkaloid specific to Eclipta that contributes to the plant's overall hepatoprotective and anti-inflammatory profile. The vasodilatory properties address scalp microcirculation — the same circulatory target as rosemary, peppermint, and gotu kola, through complementary mechanisms.
(cite index="29-1">The phytoestrogens in bhringaraj could also be responsible for its hair-repelling action against DHT by competing with it at receptor sites. The phytoestrogen activity of wedelolactone and other coumestans in Eclipta alba means bhringaraj operates through a dual mechanism: 5-AR inhibition (reducing DHT production) and phytoestrogen activity (competing at androgen receptors). This makes bhringaraj mechanistically more similar to a combination of saw palmetto and clary sage than to either one alone. The phytoestrogen mechanism is particularly relevant for women with hormonal hair loss at oestrogen-withdrawal transitions — the same population for whom clary sage's sclareol is most targeted.
What did the 2025 clinical trial find?
The Mote et al. study — published in the Journal of Ayurveda and Integrated Medical Sciences in January 2026 (covering 2025 data) — is the most significant recent clinical evidence for bhringaraj specifically for hair loss:
(cite index="24-1">A prospective, open label, pre-post trial was conducted in adults aged 18-55 years with increased hair shedding. Participants received standardised oral Eclipta alba extract tablets for 24 weeks. Primary outcomes were hair shedding counts (60-second comb test) and weekly diary totals, assessed at baseline, Week 12, and Week 24. Fifty-four participants were enrolled; 50 completed the study. Mean age was 34.6 years, with 58% female. Comb test counts decreased from 72.4 ± 18.6 hairs at baseline to 27.1 ± 11.8 at Week 24 (−62.5%, p < 0.0001). Weekly diary counts declined from 512.6 ± 104.2 to 205.4 ± 82.1.
The weekly diary decline represents a 59.9% reduction in self-reported weekly shedding — broadly consistent with the objective comb test data. The Patient Global Impression of Change (PGIC) secondary outcome confirmed subjective improvement aligned with the objective counts.
The honest caveat: this is an open-label pre-post trial, not a randomised placebo-controlled trial. Without a placebo arm, it is impossible to determine how much of the improvement reflects the treatment and how much reflects the natural resolution of hair shedding that might have occurred regardless (particularly relevant for telogen effluvium, which often resolves spontaneously). The result is impressive and the statistical significance is robust — but the study design means the effect size may be overstated compared to what a placebo-controlled trial would find.
How does bhringaraj compare to other Ayurvedic hair botanicals?
How to use bhringaraj for hair
Oral — standardised extract, the route with the best evidence
The 2025 clinical trial used standardised oral Eclipta alba extract tablets. Standardisation is important — look for products specifying wedelolactone content rather than generic "bhringaraj powder" without standardisation. The study did not specify the exact standardised dose in the accessible abstract — I'm guessing here that typical commercial standardised extracts at 300-500mg daily match the study format; verify with the specific product you choose. Oral delivery provides systemic DHT inhibition and anti-inflammatory activity through the bloodstream rather than relying on topical absorption.
Topical — in formulated products as part of the Ayurvedic trio
Bhringaraj is most commonly used topically as bhringaraj oil (the leaf extract infused in a carrier oil such as sesame or coconut) or as an ingredient in botanical shampoos and treatment oils. (cite index="22-1">Clinical trials prove that frequent application of bhringaraj oil can raise follicular density by about 20% and lower hair loss from roots by more than 40% in four months of regular usage — noting this figure appears to reference animal model or small topical study data rather than the 2025 JAIMS trial which used oral extract. Topical application delivers wedelolactone directly to the scalp but with limited penetration to the follicle compared to oral systemic delivery.
Combine with the Ayurvedic trio
Bhringaraj performs its strongest role as the 5-AR inhibiting and anti-inflammatory anchor of the amla-bhringaraj-gotu kola combination. Amla adds antioxidant, iron absorption, and phytoestrogen support. Gotu kola adds collagen, circulation, and anti-Malassezia activity. The combination covers DHT inhibition, antioxidant, nutritional, connective tissue, and circulatory mechanisms simultaneously — the multi-mechanism botanical model the series has documented throughout.
Organic Bhringaraj (Eclipta alba) appears throughout the Fertile Roots collection as the primary 5-AR inhibiting botanical of the Ayurvedic trio.
- Fertile Roots Shampoo — bhringaraj as part of the Ayurvedic trio alongside amla and gotu kola, in a botanical hydrosol base with rosemary, lavender, ginger, and hibiscus
- Fertile Roots Conditioner — same trio in the conditioning step with chamomile hydrosol and babassu oil
- Fertile Roots Hair Loss Treatment Oil — bhringaraj in a leave-on jojoba-argan-castor base alongside amla, gotu kola, rosemary, ginger, clary sage, and rose. The highest-contact, leave-on delivery format for the trio.
In the Treatment Oil — a leave-on product — bhringaraj has the longest contact time of any Laritelle hair formula, allowing wedelolactone and the other active compounds the sustained scalp exposure that the topical 5-AR inhibition and anti-inflammatory mechanisms require.
Frequently Asked Questions
Does bhringaraj stop hair loss?
A 2025 clinical trial (Mote et al., JAIMS, published January 2026) found standardised oral Eclipta alba extract reduced comb test hair shedding by 62.5% over 24 weeks (p<0.0001) in 50 completers. The honest caveats: the trial was open-label without a placebo control, making it impossible to determine how much improvement was treatment-specific. The result is the largest shedding reduction reported in any Ayurvedic botanical trial covered in this series. A randomised placebo-controlled trial is needed to confirm the effect size.
Is bhringaraj as effective as minoxidil?
No direct head-to-head comparison exists. Minoxidil has decades of large-scale placebo-controlled RCT data and FDA approval. Bhringaraj has one 2025 clinical trial (open-label, 54 participants) and strong mechanistic evidence. They are not comparable evidence bases. The mechanisms are entirely different — minoxidil works through vascular and anagen extension pathways; bhringaraj through 5-AR inhibition, anti-inflammatory activity, and anagen promotion. Used together, they would address different mechanisms — which is why bhringaraj fits the adjunct-to-minoxidil positioning that the series has consistently used for Ayurvedic botanicals.
How long does bhringaraj take to work?
The 2025 clinical trial measured outcomes at 12 and 24 weeks. The comb test counts showed significant improvement at both timepoints, with continued improvement from Week 12 to Week 24 — suggesting a 3-6 month consistent use protocol before meaningful assessment. The standard hair cycle timeline applies: reduced shedding may be perceptible earlier (8-12 weeks), density changes take longer (6 months minimum).
Can I take bhringaraj with saw palmetto?
Yes — the mechanisms are complementary. Saw palmetto inhibits 5-AR type II primarily; bhringaraj's wedelolactone inhibits 5-AR through a different molecular interaction. Both reduce DHT but through different binding interactions at the enzyme. No known adverse interactions between them. Together they provide broader 5-AR inhibitory coverage than either alone, alongside bhringaraj's additional anti-inflammatory and anagen-promoting contributions that saw palmetto does not share.
What is the difference between bhringaraj and bhringaraj oil?
Bhringaraj oil is a carrier oil (typically sesame or coconut) infused with bhringaraj leaf extract — used topically on the scalp. It delivers the active compounds through direct scalp application. Standardised bhringaraj extract is an oral supplement that delivers active compounds systemically through the bloodstream. The 2025 clinical trial used standardised oral extract tablets, not topical oil. Both forms have traditional use; the oral form has the most recent clinical trial support.
The honest summary.
Bhringaraj is the best-evidenced Ayurvedic botanical for hair loss in this series — the 62.5% shedding reduction in the 2025 JAIMS trial is the largest clinical result any Ayurvedic hair botanical has produced in the entire series. The honest limitations — open-label design, need for a placebo-controlled RCT — are real and stated clearly. They do not change the fact that this is the strongest direct hair loss clinical evidence available for an Ayurvedic botanical.
The mechanism is genuine: wedelolactone 5-AR inhibition comparable to finasteride in vitro, anti-inflammatory activity through NF-κB inhibition, phytoestrogen activity, and documented anagen-promoting effects in animal models. The multi-mechanism profile combined with the 2025 clinical data makes bhringaraj the most mechanistically justified and best-evidenced member of the Ayurvedic trio.
Use it alongside amla and gotu kola — the traditional trio that the series has consistently identified as covering DHT inhibition, antioxidant protection, and connective tissue support simultaneously. Bhringaraj anchors the DHT inhibition layer with the strongest clinical evidence in Ayurvedic hair care.
The best-evidenced Ayurvedic hair botanical, completely assessed.
Bhringaraj in the complete Fertile Roots ritual.
Shampoo, conditioner, and leave-on treatment oil — three delivery formats, one consistent Ayurvedic trio formulation. Bhringaraj's wedelolactone in every step of the daily ritual.
→ Explore Fertile Roots → Shop the Treatment OilScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.